New Drugs and Treatment Targets in Psoriasis

K Kofoed, L Skov, C Zachariae
2015 Acta Dermato-Venereologica  
In recent years, the increased understanding of the patho physiology of psoriasis has resulted in several new treat ments. The success of ustekinumab proved the importan ce of the IL23/T helper cell 17 axis in psoriatic diseases. Several new biologics targeting this axis will reach the clinic in the next years. Biologics are costly, require in jections, and some patients experience taca phylaxis, thus, the development of orally available, smallmolecu le inhibitors is desirable. Among
more » ... e. Among smallmolecules under investigation are A 3 adenosine receptor agonists, Janus kinase inhibitors, and phosphodiesterase inhibitors. We review published clinical trials, and conference ab stracts presented during the last years, concerned with new drugs under development for the treatment of pso riasis. In conclusion, our psoriasis armamentarium will be filled with several new effective therapeutic options the coming years. We need to be aware of the limitations of drug safety data when selecting new novel treatments. Monitoring and clinical registries are still important tools. NEW BIOLOGICS Interleukin-12/23 inhibitors IL-12 and IL-23 are heterodimeric pleiotropic cytokines each consisting of 2 subunits that are named
doi:10.2340/00015555-1931 pmid:25111317 fatcat:ftacwnb5dncarjddludhcmwxwy